J&J's Tibotec files HIV drug rilpivirine in Europe
This article was originally published in Scrip
Executive Summary
Tibotec Pharmaceuticals (J&J) has submitted a marketing authorisation application (MAA) to the EMA for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV.